A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with ...
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SB...
Top Cities for Short Bowel Syndrome Clinical Trials
Short Bowel Syndrome clinical trials are recruiting across 18 cities. Here are the cities with the most active studies:
About Short Bowel Syndrome
Short bowel syndrome is a condition where the body cannot absorb enough nutrients because a large portion of the small intestine is missing or damaged. It often results from surgical removal. Treatment includes specialized nutrition, medications, and sometimes intestinal transplantation.
Clinical trials are advancing new treatments for short bowel syndrome. Currently, 2 studies are recruiting a combined 54 participants across the United States. Research is being conducted by 2 organizations including NorthSea Therapeutics B.V., Hanmi Pharmaceutical Company Limited.
2026 Short Bowel Syndrome Research Landscape
As of March 2026, the short bowel syndrome clinical trial landscape includes 2 actively recruiting studies across 18 cities in the United States. These studies are collectively seeking 54 participants, with an average enrollment target of 27 per study.
Research is being led by 2 different organizations, including NorthSea Therapeutics B.V., Hanmi Pharmaceutical Company Limited.
Geographically, short bowel syndrome trials are most concentrated in Chicago, Illinois (2 trials); Boston, Massachusetts (2 trials); Scottsdale, Arizona (1 trial); San Francisco, California (1 trial); Washington D.C., District of Columbia (1 trial) and 7 other cities.
Featured Short Bowel Syndrome Studies
Highlighted recruiting studies for short bowel syndrome, selected by enrollment size and research scope.
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in ...
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SBS-associated intestinal failure (SBS-IF).
Frequently Asked Questions About Short Bowel Syndrome Clinical Trials
Are there short bowel syndrome clinical trials near me?
Yes, there are 2 short bowel syndrome clinical trials currently recruiting across 18+ cities in the United States, including Chicago, Illinois; Boston, Massachusetts; Scottsdale, Arizona. Browse the studies above to find one at a location convenient for you.
How do I join a short bowel syndrome clinical trial?
To join a short bowel syndrome clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are short bowel syndrome clinical trials free?
Yes, participation in short bowel syndrome clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of short bowel syndrome treatments are being studied?
Current short bowel syndrome clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 2 research organizations.
Is it safe to participate in short bowel syndrome clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov